logo
Plus   Neg
Share
Email

Alkermes Announces NDA Filing Acceptance For Diroximel Fumarate - Quick Facts

Alkermes plc (ALKS) and Biogen Inc. (BIIB) announced the U.S. FDA has accepted for review the New Drug Application for diroximel fumarate (BIIB098), an oral fumarate in development for the treatment of relapsing forms of multiple sclerosis. The NDA has been assigned a PDUFA target action date in the fourth quarter of 2019.

Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway, referencing Biogen's dimethyl fumarate data. If approved, Biogen intends to market diroximel fumarate under the brand name, VUMERITY.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Alibaba is upgrading its intellectual property system using blockchain technology, according to local news outlet Sohu. Alibaba Platform Management expects this to benefit mainly small and medium-sized enterprises, brands and entrepreneurs. The technology will be fully implemented in September, and thereafter, the company intends to expand it to the field of digital copyright protection. Electronics retailer Best Buy Co., Inc. (BBY) reported Thursday a 27 percent increase in profit for the first quarter from last year, which was impacted by restructuring charges, and higher revenues. Both adjusted earnings per share and revenues for the quarter topped analysts' estimates. The company also provides guidance for the second quarter and reiterated its outlook for the full-year 2020. While reporting financial results for the second quarter on Thursday, Hormel Foods Corp. (HRL) lowered its earnings and net sales guidance for the full-year 2019. For fiscal 2019, the company now projects earnings in a range of $1.71 to $1.85 per share, and net sales between $9.70 billion and $10.20...
Follow RTT